Total neoadjuvant therapy for locally advanced rectal cancer: a three-group propensity score matched study

Jiahao Zhou,Jun Huang,Zikai Zhou,Xiangbing Deng,Qingbin Wu,Ziqiang Wang
DOI: https://doi.org/10.1007/s00384-024-04610-1
IF: 2.8
2024-03-17
International Journal of Colorectal Disease
Abstract:Total neoadjuvant therapy (TNT) has emerged as a therapeutic approach for locally advanced rectal cancer (LARC). However, the optimal chemotherapy cycles within TNT remain uncertain. This study aimed to evaluate and compare the prognostic efficacy of varying cycles of chemotherapy during TNT for LARC.
gastroenterology & hepatology,surgery
What problem does this paper attempt to address?
### Problems the Paper Attempts to Solve This paper aims to evaluate and compare the prognostic effects of different chemotherapy cycles in total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC). Specifically, the research objectives are: 1. **Evaluate the impact of TNT with different chemotherapy cycles on disease-free survival (DFS) and metastasis-free survival (MFS) in patients with locally advanced rectal cancer**: By dividing patients into three groups (CRT group receiving only long-course chemoradiotherapy, STNT group receiving 1-3 cycles of chemotherapy, and LTNT group receiving 4 or more cycles of chemotherapy), the researchers hope to determine which treatment strategy provides the best prognostic outcome. 2. **Investigate whether the number of chemotherapy cycles significantly affects survival outcomes**: Although TNT has shown advantages in improving pathological complete response rate (pCR) and chemotherapy compliance, its impact on survival outcomes remains controversial. The researchers aim to further clarify the specific impact of the number of chemotherapy cycles on survival outcomes by analyzing TNT with different chemotherapy cycles. ### Research Background - **Standard Treatment Regimen**: For a long time, the standard treatment regimen for locally advanced rectal cancer has included preoperative neoadjuvant chemoradiotherapy (CRT), total mesorectal excision (TME), and postoperative adjuvant chemotherapy. Although this regimen has achieved significant improvements in local control, about one-third of patients still develop distant metastases. - **Advantages and Controversies of TNT**: Total neoadjuvant therapy (TNT) increases chemotherapy compliance and pathological complete response rate (pCR) by adding chemotherapy cycles before and after CRT. However, current research results are inconsistent regarding whether TNT can significantly improve survival outcomes. - **Uncertainty of Chemotherapy Cycles**: Different studies have used varying numbers of TNT chemotherapy cycles, making it difficult to determine the optimal number of chemotherapy cycles. Therefore, this study systematically evaluates the impact of different numbers of TNT chemotherapy cycles on survival outcomes using the propensity score matching (PSM) method. ### Research Methods - **Patient Selection**: Retrospectively included patients with locally advanced rectal cancer who received TNT or CRT treatment and underwent TME surgery at the hospital between 2015 and 2020. - **Grouping**: Patients were divided into three groups based on neoadjuvant treatment strategy: CRT group, STNT group, and LTNT group. - **Statistical Analysis**: The PSM method was used to adjust baseline characteristics to reduce confounding bias, and the Kaplan-Meier method was used to analyze survival outcomes. ### Main Findings - **Overall Survival Outcomes**: Compared with CRT, the 5-year DFS and MFS of the STNT and LTNT groups were significantly improved (DFS: 59.7% vs. 77.8% vs. 76.5%, p = 0.027; MFS: 65.1% vs. 81.3% vs. 81.4%, p = 0.030). However, there was no significant difference in DFS and MFS between the STNT and LTNT groups. - **Subgroup Analysis**: In subgroups with tumor distance from the anal verge ≥5 cm, clinical T3 stage, clinical N-positive status, or mesorectal fascia involvement, the survival advantages of the STNT and LTNT groups remained significant. ### Conclusion - **Main Conclusion**: Compared with CRT, both STNT and LTNT significantly improved DFS and MFS in LARC patients, and the number of chemotherapy cycles in TNT did not significantly affect the outcomes. - **Clinical Significance**: These findings support TNT as a treatment option for LARC, but further research is needed to determine the optimal number of chemotherapy cycles.